MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)

被引：72
|
作者：
Toffoli, G [1 ]
Veronesi, A
Boiocchi, M
Crivellari, D
机构：
[1] Natl Canc Inst, Ctr Riferimento Oncol, Div Expt Oncol 1, Aviano, PN, Italy
[2] Natl Canc Inst, Ctr Riferimento Oncol, Div Med Oncol C, Aviano, PN, Italy
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷 / 03期
关键词：
D O I：
10.1023/A:1008337900349
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：373 / 374
页数：2
相关论文
共 50 条
  • [21] Genetic predisposition in developing toxicity after the first cycle of adjuvant cyclofosphamide, fluorouracil (FU) and methotrexate (MTX) -: CMF in breast cancer patients is methylene tetrahydrofolate reductase (MTHFR) gene polymorphism (677C→T) a risk factor?
    Toffoli, G
    Scuderi, C
    Crivellari, D
    Magri, MD
    Tolusso, D
    Spazzapan, S
    Sartor, F
    Sorio, R
    Boiocchi, M
    Veronesi, A
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
  • [22] CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL FOR BREAST-CANCER
    HOWELL, A
    GEORGE, WD
    CROWTHER, D
    RUBENS, RD
    BULBROOK, RD
    BUSH, H
    HOWAT, JMT
    SELLWOOD, RA
    HAYWARD, JL
    FENTIMAN, IS
    CHAUDARY, M
    LANCET, 1984, 2 (8398): : 307 - 311
  • [23] Doxorubicin and Cyclophosphamide versus Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Adjuvant Chemotherapy in Breast Cancer
    Livi, L.
    Saieva, C.
    Borghesi, S.
    Cardillo, C. De Luca
    Scotti, V.
    Mangoni, M.
    Greto, D.
    Cataliotti, L.
    Paiar, F.
    Bianchi, S.
    Biti, G. P.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (05) : 558 - 565
  • [24] MTHFR Polymorphism Is Associated With Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment
    Zhang, Wenchao
    Liu, Zhongyue
    Yang, Zhimin
    Feng, Chengyao
    Zhou, Xiaowen
    Tu, Chao
    Li, Zhihong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [25] Doxorubicin 75mg/M2 followed by cyclophosphamide, methotrexate, and fluorouracil (A=> CMF) in the adjuvant treatment of node positive breast cancer:: Outcome and toxicity in 136 patients.
    Rizel, S
    Ben-David, M
    Brenner, HJ
    Stemmer, SM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 88S - 88S
  • [26] Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer
    Hajime Abe
    Tsuyoshi Mori
    Yuki Kawai
    Hirotomi Cho
    Yoshihiro Kubota
    Tomoko Umeda
    Yoshimasa Kurumi
    Tohru Tani
    International Journal of Clinical Oncology, 2013, 18 : 487 - 491
  • [27] Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer
    Abe, Hajime
    Mori, Tsuyoshi
    Kawai, Yuki
    Cho, Hirotomi
    Kubota, Yoshihiro
    Umeda, Tomoko
    Kurumi, Yoshimasa
    Tani, Tohru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 487 - 491
  • [28] A RANDOMIZED ADJUVANT STUDY OF CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL (CMF) WITH AND WITHOUT RADIATION-THERAPY (RT) FOR STAGE-II BREAST-CANCER
    MUSS, H
    COOPER, MR
    FERREE, C
    RICHARDS, F
    STUART, J
    WHITE, D
    RHYNE, L
    SPURR, C
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 399 - 399
  • [29] Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’
    Romano Demicheli
    Rosalba Miceli
    Cristina Brambilla
    Laura Ferrari
    Angela Moliterni
    Milvia Zambetti
    Pinuccia Valagussa
    Gianni Bonadonna
    Breast Cancer Research and Treatment, 1999, 53 : 209 - 215
  • [30] Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'
    Demicheli, R
    Miceli, R
    Brambilla, C
    Ferrari, L
    Moliterni, A
    Zambetti, M
    Valagussa, P
    Bonadonna, G
    BREAST CANCER RESEARCH AND TREATMENT, 1999, 53 (03) : 209 - 215
12345